The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.
